In the face of the COVID-19 pandemic, the scientific community has rallied to understand, combat, and prevent the spread of the SARS-CoV-2 virus. At Rockland, our commitment to aiding this global effort is evident through our production of high-quality antibodies against SARS-CoV-2. Our offerings, including antibodies targeting the Nucleocapsid and Spike proteins, are essential tools for vaccine development, drug discovery, diagnostics, and broader COVID-19 research. Explore our selection to support your critical research needs:
Precise targeting: Antibodies for SARS-CoV-2 Spike, Nucleocapsid, and other viral proteins
High specificity: Monoclonal antibodies distinguish unique epitopes for accurate detection
Versatile detection: Polyclonal antibodies ensure consistent recognition of viral variants
